**GU Cancer Clinical Trials**

**Non-Metastatic**

**Metastatic**

**Both**

UCI 16-19 ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy (Uchio)

UCI 16-90 A Phase III, Multicenter, Randomized Study Of Atezolizumab (Anti−PD−L1 Antibody) In Combination With Enzalutamide Versus Enzalutamide Alone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of An Androgen Synthesis Inhibitor And Failure Of, Ineligibility For, Or Refusal Of A Taxane Regimen (Mar)

UCI 17-10 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib plus Abiraterone plus Prednisone/ Prednisolone, Relative to Placebo plus Abiraterone plus Prednisone/ Prednisolone in Adult Male Patients with Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer (Mar)

UCI 17-25** A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/ Prednisone) (Uchio)

UCI 17-41** A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) (Uchio)

UCI 17-86** Phase 1 Trial of Efficacy and Feasibility of Robot Assisted Salvage Pelvic Lymph Node Dissection (RS-PLND) or Robot Assisted Salvage Pelvic Mass Resection (RS-PMR) Post-Robot Assisted Radical Prostatectomy (Ahlering)

**SUSPENDED** UCI 16-76 Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) (Mar)

UCI 17-48 HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer (Uchio)

**Opening soon**

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

Version 02/18
**Opening soon**

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

**UCI 13-03** Office-Based Percutaneous Ultrasound-Guided Renal Biopsy (Landman)

**UCI 16-57** Phase-I trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas (Landman)

**UCI 16-84** A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti–PD-L1 Antibody) As Adjuvant Therapy In Patients With Renal Cell Carcinoma At High Risk Of Developing Metastasis Following Nephrectomy (Uchio)

**UCI 17-04** Evaluation of Virtual Reality Renal Models as Educational and Preoperative Planning Tools for Partial Nephrectomy: A Pilot Study (Landman)

**UCI 11-19** Evaluation of Peritumoral Renal Adipose Tissue to Renal Cancer Aggressiveness (Landman)

**UCI 17-67** Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat Compared to Sunitinib or Pazopanib in Participants with Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (Keynote 679) (Fruehauf)
**Opening soon**

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu
**GU Cancer Clinical Trials**

**ECOG EAY131** Molecular Analysis for Therapy Choice (MATCH) (Bota)

**SWOG S1609** DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

**UCI 16-96** A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)

**UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

---

**Prostate/Renal**

**UCI 16-01** Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) (Nelson)

---

**Prostate/Bladder**

**UCI 17-90** A Two-Part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients with HER2-Positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy (Ou)

---

**Renal/Bladder**

**UCI 17-58** Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas (Pinter-Brown)

---

**All**

**UCI 07-40** Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Ou)

---

**Opening soon**

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

Version 02/18